Fosaprepitant
Emend, Focinvez, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emend | New Drug Application | 2026-02-20 |
| focinvez | New Drug Application | 2025-10-10 |
| fosaprepitant | ANDA | 2025-12-24 |
| fosaprepitant dimeglumine | ANDA | 2026-03-19 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC | |||
| 2025-05-02 | D-186 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fosaprepitant Dimeglumine, Focinvez, Steriscience | |||
| 11065265 | 2039-01-11 | DP | |
ATC Codes
No data
Clinical
Clinical Trials
166 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | 8 | 27 | 36 | 19 | 18 | 105 |
| Nausea | D009325 | — | R11.0 | 4 | 24 | 28 | 17 | 19 | 89 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 3 | 5 | 11 | 7 | 27 |
| Neoplasms | D009369 | — | C80 | 3 | 4 | 5 | 4 | 6 | 20 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 4 | 2 | 2 | 9 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | 1 | 3 | 6 |
| Leukemia | D007938 | — | C95 | — | 2 | — | 1 | 2 | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | 1 | 3 | 4 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | 1 | — | 3 |
| Pruritus | D011537 | — | L29 | 1 | 1 | — | 1 | — | 3 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | 3 | — | 3 | 9 |
| Depression | D003863 | — | F33.9 | — | — | 9 | — | — | 9 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | — | — | 9 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 9 | — | — | 9 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 1 | 1 | — | 2 | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | 1 | — | 1 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | 1 | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | 1 | — | — | 2 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | 1 | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | — | — | 2 | — | — | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | 1 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | 2 | 3 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | 2 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 2 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | 1 | — | — | 1 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 1 | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | — | 2 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
| Heroin dependence | D006556 | EFO_0004240 | — | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | — | — | — | — | 1 |
| Brain injuries | D001930 | — | S06.9 | 1 | — | — | — | — | 1 |
| Intracranial hypertension | D019586 | EFO_1000992 | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 3 | 3 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 2 | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 2 | 2 |
| Plasmacytoma | D010954 | — | C90.3 | — | — | — | — | 2 | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 2 | 2 |
| Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fosaprepitant |
| INN | fosaprepitant |
| Description | Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 172673-20-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1199324 |
| ChEBI ID | 64321 |
| PubChem CID | 219090 |
| DrugBank | DB06717 |
| UNII ID | 6L8OF9XRDC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emend – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 850 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,741 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use